Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Early access program opens for upadacitinib in Crohn's, colitis, arthritis, and eczema

NCT ID NCT04159597

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access This study
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This program offers early access to upadacitinib (Rinvoq) for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis who have no other suitable treatments and cannot join ongoing clinical trials. A doctor must decide if the potential benefits outweigh the risks. The drug is taken as an oral solution.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
upadacitinib (Rinvoq)
What this could lead to
If successful, this program could provide early access to upadacitinib for people with serious inflammatory conditions who have no other good options.
What could go wrong
This is an expanded access program, not a formal trial, so data on safety and effectiveness is limited. Upadacitinib may have side effects, and not everyone will qualify.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Exclusion Criteria: * There are other suitable treatment options. * The participant qualifies for ongoing clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia areata atopic eczema Axial Spondyloarthritis Crohn disease Giant Cell Arteritis hidradenitis suppurativa juvenile idiopathic arthritis psoriatic arthritis rheumatoid arthritis Spondylarthritis spondyloarthropathy systemic lupus erythematosus temporal arteritis ulcerative colitis vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata Atopic dermatitis Axial spondyloarthritis Crohn disease Giant cell arteritis Hidradenitis suppurativa Idiopathic arthritis (including sjia, pjia, or jpsa) Non-radiographic axial Non-segmental vitiligo Psoriatic arthritis Rheumatoid arthritis Spondyloarthritis Systemic lupus erythematosus Ulcerative colitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.